Overview
Guided by policy, commercial health insurance is shifting from post-claim payout to full-cycle health management. On November 1, the NFRA’s revised Rules on Property Insurance Product Development took effect—8 chapters, 41 articles, listing eight prohibited development scenarios, clarifying corporate responsibility and strengthening full-lifecycle product management. Meanwhile, medical-insurance data collaboration is breaking through: several regions use privacy computing and trusted data spaces for pre-underwriting risk control and one-stop direct claims.
The 2026 Full-Lifecycle Health Innovation Forum (Oct 31–Nov 1, Nansha) noted China has 325 million people aged 60+ and ~50 million disabled/semi-disabled, requiring health insurance to move from cost reimbursement to multi-value, full-cycle care.
Background & Interpretation
1. Regulatory and Industry Context
The September 2025 NFRA guidance promoted health-insurance–health-management integration; the July 2026 15th Five-Year health plan encouraged new products covering intervention, specialty care and innovative drugs. The P&C rules regulate products at the source, ending the anything insurable gimmick era.
2. Core Drivers and Underlying Mechanism
The shift rests on disease risk moving from uncontrollable random to predictable and manageable, weakening static actuarial models, while basic medical insurance’s expansion squeezes homogeneous reimbursement products. Compliant medical-insurance data flow (data stays in domain, usable but invisible) enables underwriting risk control and direct claims, turning health management into real risk control.
3. Market Structure and Value-Chain Impact
Firms like Fosun United embed long-term health management in policy clauses, linking top-tier hospitals and wearables—one product exceeded 100m yuan in a year with 98% service usage. Third parties like Mx Health use AI OS to aggregate innovative drug and million-medical data across the product-claims chain. Inclusive insurance reaches counties via postal and medical data.
Implications & Outlook
Near-term, P&C rules lift product quality and curb gimmicks; medium-term, deep health-insurance–management fusion will reshape payout structures and service boundaries. Watch the scope of authorized medical-data operations, service usage vs. cost control, and the pace of innovative drugs entering commercial insurance.
Takeaways for Industry Participants
Insurers should embed health management in clauses and closed-loop services, not as add-ons; medical and data institutions can build compliant data spaces to unlock synergy; regulators should balance innovation and consumer protection and standardize one-stop settlement.
This column compiles industry information and shares technical perspectives; it does not constitute investment advice.